GeoVax Labs, Inc. — Form 8-K
Filed July 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
GeoVax reported Q2 2026 net loss of $4.43M ($0.97/share) versus $5.37M ($8.74/share) YoY, with zero government contract revenue following BARDA's April 2025 contract termination for the COVID-19 program. Cash position remained flat at $3.1M as of June 30, 2026 versus December 31, 2025. The company is advancing GEO-MVA (MVA vaccine for mpox/smallpox) toward a planned Q4 2026 pivotal immunobridging study under expedited EMA regulatory pathway, while discontinuing GEO-CM04S1 COVID development.
Why this rating
Loss of $2.5M annual BARDA revenue (18% of company size) is material negative; offsetting positive: GEO-MVA milestone advancing on expedited pathway with cGMP material ready, cost discipline reducing burn. Critical execution risk: $3.1M cash must fund pivotal trial launch—no margin for error.
See more from July 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.